Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

Tue, 21st May 2024 17:04

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

The FTSE 100 index closed down 7.75 points, 0.1%, at 8,416.45. The FTSE 250 ended down 89.96 points, 0.4%, at 20,783.37, and the AIM All-Share closed down 2.85 points, 0.4%, at 807.09.

The Cboe UK 100 ended down 0.1% at 840.04, the Cboe UK 250 closed down 0.3% at 18,202.46, and the Cboe Small Companies ended up 0.7% at 16,646.41.

In European equities on Tuesday, the CAC 40 in Paris ended down 0.7%, while the DAX 40 in Frankfurt ended down 0.2%.

Investors this week are eyeing Wednesday's inflation reading for the UK. It is expected to show that the rate of consumer price inflation moderated markedly to 2.1% in April, from 3.2% in March, according to FXStreet cited consensus.

Core CPI, excluding food and inflation, is expected to come in at 3.6% in April, decelerating from 4.2% a month earlier.

Analysts at Lloyds said: "this obviously remains more elevated than the headline rate, while notably services inflation is expected to still be above 5%. So while the expected decline in inflation is welcome news, it is still unclear whether BoE policymakers will regard it as sufficient progress to justify an interest rate cut."

Meanwhile, on Tuesday, the International Monetary Fund said the UK economy is set for a "soft landing", and it urged the Bank of England to be mindful of rate cut timing.

The IMF said in a new report on the health of the UK economy that gross domestic product in the country is expected to grow by 0.7% for 2024, following 0.6% growth over the first quarter.

It represents an upgrade from the IMF's previous prediction of 0.5% growth for the year.

The economic calendar for Wednesday also has the release of the latest US Federal Open Market Committee meeting.

"I believe investors are now looking for new signals regarding when the Federal Reserve (Fed) will begin cutting interest rates. They are awaiting the FOMC minutes to better understand officials' views on policy regarding interest rate expectations," said Rania Gule at XS.com.

The pound was quoted at USD1.2715 at the London equities close Tuesday, higher compared to USD1.2702 at the close on Monday. The euro stood at USD1.0856 at the European equities close Tuesday, down against USD1.0862 at the same time on Monday. Against the yen, the dollar was trading at JPY156.10, lower compared to JPY156.14 late Monday.

In the FTSE 100, AstraZeneca closed up 2.3%.

Ahead of a Tuesday investor day, AstraZeneca set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."

The target, which the Cambridge pharmaceuticals manufacturer described as "bold," would represent a 75% jump from the USD45.81 billion it achieved in 2023.

AJ Bell Investment Director Russ Mould thinks AstraZeneca is now "reaching for the stars" with its new target.

Schroders was up 3.9%.

UBS thinks the recent underperformance of Schroders PLC offers investors an attractive risk-reward profile.

As a result, the Swiss broker upgraded the London-headquartered asset management company to 'buy' from 'neutral'.

In the FTSE 250, Greencore shot up 19%.

The Dublin-based producer of convenience foods said in the first half ended March 29, it swung to a pretax profit of GBP14.7 million, from a pretax loss of GBP6.2 million the year prior.

Revenue fell 6.4% to GBP866.1 million from GBP925.8 million. The revenue decline reflects its decision to leave a "number of low margin contracts".

Looking ahead, Greencore currently expects a full year adjusted operating profit in the range of GBP86 million to GBP88 million, up from GBP76.3 million last year. Its guidance is ahead of "current market expectations".

Further, if trading continues as expected, Greencore said it will pay a dividend for the first time since financial 2019.

On the other end of the index, SSP lost 9.0%.

In the six months ended March 31, the London-based travel food outlet operator said pretax profit fell 19% to GBP12.8 million from GBP15.8 million a year earlier.

This was despite revenue rising 15% to GBP1.52 billion from GBP1.32 billion, as operating costs rose 15% to GBP1.46 billion from GBP1.27 billion.

Despite a falling bottom-line, SSP maintained its first half dividend at 1.2 pence per share.

Amongst London's small-caps, XP Power shares jumped 48% to 1,720.00 pence. The firm confirmed it rejected takeover approaches by New York-listed Advanced Energy Industries.

The maker of power control systems received approaches valuing it at GBP17 per share in October, at GBP18.50 in November and finally at GBP19.50 two weeks ago.

The latest proposal gives it an equity value of GBP468 million, and GBP571 million when including debt.

XP Power said the bids "fundamentally undervalues the company and its prospects".

Stocks in New York were higher at the London equities close, with the DJIA, the S&P 500 index and the Nasdaq Composite all up 0.1%.

Focus this week will be on earnings from chipmaker Nvidia, whose AI-driven stock market surge has been a key theme in recent months.

Brent oil was quoted at USD82.66 a barrel at the London equities close Tuesday, down from USD83.65 late Monday. Gold was quoted at USD2,425.40 an ounce at the London equities close Tuesday, up slightly against USD2,423.50 at the close on Monday.

In Wednesday's UK corporate calendar, there are full year results from British Land, Marks & Spencer and Severn Trent.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.